MERGENT OTC INDUSTRIAL

Transcription

1 MERGENT OTC INDUSTRIAL NEWS REPORTS Friday, May 26, 2017 Volume 48 No 5 NEW COMPANY DESCRIPTIONS (For details on individual listings, see the News Section of this issue) WhereverTV Broadcasting Corp NAME CHANGES (For details on individual listings, see the News Section of this issue) PharmAthene Inc (to Altimmune Inc) Tokai Pharmaceuticals Inc (to Novus Therapeutics Inc) Travelzoo Inc (to Travelzoo) FLOWERSCOM, INC Earnings, 9 mos to (Consol $000): 04/02/17 03/27/16 Total Revenues 954, ,629 Cost & expenses 871, ,474 Deprec, depl & amort 25,656 24,279 Operating income 57,157 58,876 Interest expense 4,796 5,292 Other income (expense), net ,151 Net before taxes 52,931 68,735 Income taxes 16,903 21,813 Net income 36,028 46,922 Primary $055 $074 Fully Diluted $053 $071 Full Diluted 67,747 67,053 Year-end 65,335 65,432 2U INC Acquisition Development On May 2, 2017, Co announced that it has entered into an agreement to acquire GetSmarter (incorporated as Get Educated International Proprietary Limited), a leader in collaborating with universities to offer premium online short courses to working professionals Co will acquire GetSmarter in all-cash transaction for approximately $103,000,000, subject to certain purchase price adjustments, and an earn-out payment of up to $20,000,000 in cash, subject to achievement of certain financial milestones in calendar years 2017 and 2018 Subject to various closing conditions, the acquisition is expected to close during the third quarter of U INC Total Revenues 64,829 47,444 Cost & expenses 68,464 50,890 Operating income (3,635) (3,446) Interest income Interest expense 26 Net income (3,439) (3,380) Primary $(007) $(007) Fully Diluted $(007) $(007) Full Diluted 47,237 45,953 Year-end 47,347 46,263 Cash & equivalents 142,889 Current assets 180,712 Net property & equip 29,659 Total assets 260,680 Current liabilities 50,839 Stockholders equity 195,744 Net current assets 129,873 NOTICE Items in this issue will be listed online weekly and printed monthly 3D SYSTEMS CORP (DE) Total Revenues 156,431, ,555,000 Cost & expenses 165,502, ,314,000 Operating income (9,071,000)(16,759,000) Interest income 167, ,000 Other income (expense), net (65,000) (1,188,000) Foreign currency 329,000 1,518,000 Net before taxes (8,870,000)(16,633,000) Income taxes 1,041,000 1,179,000 Net income (9,911,000)(17,812,000) Primary $(009) $(016) Fully Diluted $(009) $(016) Full Diluted 111,289, ,197,000 Year-end 113,788, ,981,000 Cash & equivalents 161,662,000 Inventories 105,105,000 Current assets 409,257,000 Net property & equip 84,803,000 Total assets 865,630,000 Current liabilities 141,700,000 Long-term debt 7,454,000 Stockholders equity 637,504,000 Net current assets 267,557,000 3DICON CORP Annual Report Consolidated Income Statement, Years Ended Dec 31 ($): (revised) Sales 15,000 Grant income 5,122 70,748 Total income 5,122 85,748 Research & development expenses 300,985 47, ,550 General & administrative expenses 383, ,012 1,065,167 Interest expenses 60,082 57,787 75,735 Total expenses 744, ,537 1,339,452 (744,851) (900,415) (1,253,704) - basic 372,462, ,586, ,420,243 - diluted 372,462, ,586, ,420,243 Year end shares outstanding 1,481,754, ,370,953, ,674,567 Net earnings (loss) per share - basic $(000) $(000) $(000) Net earnings (loss) per share - diluted $(000) $(000) $(000) Total number of employees Number of common stockholders and prior periods for Coretec Industries, LLC prior to reverse merger with 3DIcon Corp; 2 Reclassified to conform with 2015 presentation; 3 Shares increased due to the effect of warrant and options exercised, debentures converted, stock issued for service and liabilities and preferred stock converted to common shares; 4 Shares increased due to the effects of warrants and options exercised, conversion of debenture and preferrred stock, stock issued for services, liabilities, shares subject to expired put call restored; 5 As of April 7, 2017; 6 As of March 30, 2016; 7 As of March 27, 2015; 8 Approximately Consolidated Balance Sheet, Years Ended Dec 31 ($): Cash ,121 Prepaid expenses 44,854 21,321 Other intangible assets 12,778 Total current assets 58,226 32,442 Furniture & fixtures 7,805 Less: Accumulated depreciation 1,674 Net property & equipment 6,131 Patents, net 1,379,943 Goodwill 166,000 Deposits - other 2,315 2,315 Total other assets 1,548,258 Total assets 1,612,615 34,757 Current maturities of convertible notes & debentures payable 183,402 Notes & debentures payable 114,259 Warrant exercise advances 55 Accounts payable 823,695 Accounts payable & accrued expenses 351,143 Accrued interest payable - related party 71,309 Accrued interest payable 17,615 Accrued salaries 317,134 Accrued interest on debentures 49,262 Total current liabilities 554,326 1,373,548 Term loan 1,054,325 Notes payable - related party 1,054,325 Total liabilities 1,608,651 1,373,548 Preferred stock 69 Preferred stock - Series A 69 Preferred stock - Series B 1,312 Common stock 296, ,191 Additional paid-in capital 586,336 20,545,939 Retained earnings (accumulated deficit) (880,104) (22,158,990) Total stockholders equity (deficiency) 3,964 (1,338,791) and prior periods for Coretec Industries, LLC prior to reverse merger with 3DIcon Corp 3DICON CORP Auditor s Report Auditor s Report The following is an excerpt from the Report of the Independent Auditors, HOGANTAYLOR LLP, as it appeared in Co s K: "In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of 3DIcon Corporation and its Subsidiary as of December 31, 2016, and the results of their operations and their cash flows for the year

2 766 MERGENT OTC INDUSTRIAL NEWS May 26, 2017 then ended in conformity with US generally accepted accounting principles The accompanying financial statements have been prepared assuming that the Company will continue as a going concern As discussed in Note 1 to the financial statements, the Company has insufficient revenue and capital commitments to fund the development of its planned products and to pay operating expenses This raises substantial doubt about the Company s ability to continue as a going concern Management s plans in regard to these matters also are described in Note 1 The financial statements do not include any adjustments that might result from the outcome of this uncertainty As discussed in Note 1 to the financial statements, the Company entered into a share exchange agreement treated as a reverse acquisition under the purchase method of accounting The consolidated statements of operations reflect the historical results of Coretec Industries, LLC (the accounting acquirer) Other basis of presentation matters are also described in Note 1" A-MARK PRECIOUS METALS, INC Earnings, 9 mos to Mar 31(Consol $000): Total Revenues 5,662,859 5,048,829 Cost & expenses 5,655,388 5,038,173 Operating income 9,196 12,816 Interest income 9,101 6,365 Interest expense 7,388 4,214 Other income (expense), net Foreign currency 12 9 Net before taxes 9,466 13,429 Income taxes 3,482 5,226 Net income 5,984 8,203 Primary $083 $118 Fully Diluted $082 $115 Full Diluted 7,122 7,112 Year-end 7,031 6,997 AAON, INC Net Sales 86,078 85,422 Cost & expenses 71,621 68,596 Operating income 14,457 16,826 Other income (expense), net Net before taxes 14,528 17,017 Income taxes 4,311 5,466 Net income 10,217 11,551 Primary $019 $022 Fully Diluted $019 $022 Full Diluted 53,190 53,593 Year-end 52,623 Cash & equivalents 34,743 Inventories 55,988 Current assets 146,210 Net property & equip 118,417 Total assets 265,283 Current liabilities 41,122 Stockholders equity 211,795 Net current assets 105,088 ACACIA COMMUNICATIONS INC Total Revenues 114,667 84,489 Cost & expenses 84,786 68,551 Operating income 29,881 15,938 Other income (expense), net (38) 228 Net before taxes 30,288 16,175 Income taxes (5,421) 1,577 Net income 35,709 14,598 Balance for common 35,709 2,698 Primary $093 $044 Fully Diluted $086 $030 Full Diluted 41,654 8,867 Year-end 38,516 6,805 Cash & equivalents 271,325 Inventories 33,684 Current assets 437,723 Net property & equip 27,292 Total assets 548,423 Current liabilities 70,611 Stockholders equity 475,983 Net current assets 367,112 ACACIA RESEARCH CORP Total Revenues 8,854,000 24,721,000 Cost & expenses 20,430,000 34,423,000 Operating income (11,576,000) (9,702,000) Other income (expense), net 696,000 (3,000) Net before taxes (10,880,000) (9,705,000) Income taxes 1,241, ,000 Net income (12,121,000) (9,897,000) Primary $(024) $(020) Fully Diluted $(024) $(020) Full Diluted 50,333,056 49,925,550 Year-end 48,803,999 50,458,905 Cash & equivalents 54,321,000 Current assets 169,682,000 Net property & equip 94,000 Total assets 272,861,000 Current liabilities 14,790,000 Stockholders equity 256,128,000 Net current assets 154,892,000 ACADIA HEALTHCARE COMPANY INC Total Revenues 679,194, ,813,000 Cost & expenses 597,097, ,359,000 Operating income 48,484,000 32,479,000 Net before taxes 48,484,000 32,479,000 Income taxes 13,711,000 7,110,000 Net income 34,773,000 25,369,000 Primary $040 $031 Fully Diluted $040 $031 Full Diluted 86,908,000 83,420,000 Year-end 86,916,624 86,539,997 Cash & equivalents 43,087,000 Inventories 4,723,000 Current assets 424,013,000 Net property & equip 2,749,538,000 Total assets 6,065,790,000 Current liabilities 335,857,000 Long-term debt 3,246,577,000 Stockholders equity 2,235,933,000 Net current assets 88,156,000 ACADIA PHARMACEUTICALS INC Total Revenues 15,286,000 4,000 Net Sales 15,286,000 Cost & expenses 104,092,000 50,266,000 Operating income (88,806,000)(50,262,000) Net income (87,843,000)(49,762,000) Primary $(072) $(045) Fully Diluted $(072) $(045) Full Diluted 121,651, ,346,000 Year-end 121,986, ,773,316 Cash & equivalents 157,383,000 Inventories 3,881,000 Current assets 489,753,000 Net property & equip 3,471,000 Total assets 503,013,000 Current liabilities 45,265,000 Stockholders equity 457,524,000 Net current assets 444,488,000 ACCELERON PHARMA, INC Total Revenues 3,705 18,201 Cost & expenses 29,563 22,157 Operating income (25,858) (3,956) Interest income Other income (expense), net (45) 8,683 Net before taxes (25,401) Income taxes 6 Net income (25,407) 5,061 Balance for common (25,407) 5,061 Primary $(066) $014 Fully Diluted $(066) $013 Full Diluted 38,404 38,666 Year-end 38,596 37,171 Cash & equivalents 33,157 Current assets 149,033 Net property & equip 7,107 Total assets 229,129 Current liabilities 15,193 Stockholders equity 208,320 Net current assets 133,840 ACCURAY INC (CA) Earnings, 9 mos to Mar 31(Consol $000): Total Revenues 271, ,827 Cost & expenses 283, ,740 Operating income (12,638) (1,913) Other income (expense), net (11,044) (14,124) Net before taxes (23,682) (16,037) Income taxes 642 2,260 Net income (24,324) (18,297) Primary $(030) $(023) Fully Diluted $(030) $(023) Full Diluted 82,268 80,320 Year-end 83,000 ACELRX PHARMACEUTICALS INC Total Revenues 3,109 3,025 Cost & expenses 15,182 11,547 Operating income (12,073) (8,522) Net before taxes (10,979) Income taxes 2 Net income (15,551) (10,981) Primary $(034) $(024) Fully Diluted $(034) $(025) Full Diluted 45,348 45,297 Year-end 45,371 45,312 Cash & equivalents 72,332 Inventories 1,852 Current assets 77,971 Net property & equip 10,245 Total assets 88,444 Current liabilities 12,753 Long-term debt 16,584 Stockholders equity (19,656) Net current assets 65,218

3 May 26, 2017 MERGENT OTC INDUSTRIAL NEWS 767 ACETO CORP Earnings, 9 mos to Mar 31(Consol $000): Net Sales 443, ,100 Cost & expenses 420, ,019 Operating income 23,351 46,081 Interest expense 10,223 4,766 Net before taxes 14,358 43,620 Income taxes 4,949 15,628 Net income 9,409 27,992 Primary $030 $096 Fully Diluted $030 $095 Full Diluted 31,792 29,536 Year-end 30,105 29,585 ACHAOGEN, INC Cost & expenses 25,348 17,670 Operating income (17,885) (11,821) Interest expense Other income (expense), net (14,668) 62 Net income (33,259) (12,197) Primary $(093) $(066) Fully Diluted $(093) $(066) Full Diluted 35,726 18,398 Year-end 35,846 Cash & equivalents 37,639 Current assets 147,074 Net property & equip 8,449 Total assets 155,806 Current liabilities 25,412 Long-term debt 18,192 Stockholders equity 78,637 Net current assets 121,662 ACHILLION PHARMACEUTICALS INC Cost & expenses 21,143 18,718 Operating income (21,143) (18,718) Interest income 1, Interest expense Net income (20,152) (18,054) Primary $(015) $(013) Fully Diluted $(015) $(013) Full Diluted 136, ,640 Year-end 136, ,640 Cash & equivalents 43,079 Current assets 383,426 Net property & equip 3,281 Total assets 393,353 Current liabilities 10,764 Long-term debt 243 Stockholders equity 382,346 Net current assets 372,662 ACI WORLDWIDE INC Total Revenues 231, ,066 Cost & expenses 205,468 66,146 Operating income 3, ,712 Other income (expense), net 649 (334) Net before taxes (5,782) 126,114 Income taxes (4,174) 36,970 Net income (1,608) 89,144 Primary $(001) $075 Fully Diluted $(001) $074 Full Diluted 116, ,938 Year-end 118,039 Cash & equivalents 99,744 Current assets 340,867 Net property & equip 77,979 Total assets 1,830,806 Current liabilities 264,569 Long-term debt 679,133 Stockholders equity 770,273 Net current assets 76,298 ACLARIS THERAPEUTICS INC Cost & expenses 12,930 13,139 Operating income (12,930) (13,139) Other income (expense), net Net income (12,559) (13,039) Primary $(048) $(065) Fully Diluted $(048) $(065) Full Diluted 26,081 20,172 Year-end 26,097 20,317 Cash & equivalents 23,677 Current assets 157,349 Net property & equip 706 Total assets 166,210 Current liabilities 5,637 Stockholders equity 160,289 Net current assets 151,712 ACORDA THERAPEUTICS INC Total Revenues 119,386, ,904,000 Net Sales 112,593, ,148,000 Cost & expenses 134,659, ,095,000 Operating income (15,273,000)(17,191,000) Interest income 38, ,000 Other income (expense), net 10,442,000 Net before taxes (19,822,000)(10,257,000) Income taxes (918,000) (9,737,000) Net income (18,904,000) (520,000) Primary $(041) $(001) Fully Diluted $(041) $(001) Full Diluted 45,808,000 44,815,000 Year-end 46,758,241 45,962,533 Cash & equivalents 133,619,000 Inventories 46,054,000 Current assets 248,152,000 Net property & equip 37,132,000 Total assets 1,319,842,000 Current liabilities 119,335,000 Long-term debt 326,366,000 Stockholders equity 676,127,000 Net current assets 128,817,000 ACTIVISION BLIZZARD, INC Total Revenues 1,726,000 1,455,000 Cost & expenses 1,233, ,000 Operating income 493, ,000 Net before taxes 453, ,000 Income taxes 27,000 46,000 Net income 426, ,000 Balance for common 426, ,000 Primary $057 $049 Fully Diluted $056 $048 Full Diluted 761, ,000 Year-end 753, ,007 Cash & equivalents 3,248,000 Inventories 48,000 Current assets 4,356,000 Net property & equip 245,000 Total assets 16,921,000 Current liabilities 2,239,000 Long-term debt 4,393,000 Stockholders equity 9,436,000 Net current assets 2,117,000 ACTUA CORP Total Revenues 30,507,000 25,186,000 Cost & expenses 37,726,000 34,705,000 Operating income (10,882,000)(13,101,000) Other income (expense), net (91,000) (136,000) Gains or losses 958,000 46,000 Net before taxes (9,887,000)(13,176,000) Income taxes 265, ,000 Income contin oper (13,302,000) Net income (10,152,000)(15,383,000) Primary $(030) $(038) Fully Diluted $(030) $(038) Full Diluted 32,113,000 37,293,000 Year-end 33,948,000 39,959,000 Cash & equivalents 80,436,000 Current assets 106,713,000 Net property & equip 5,247,000 Total assets 432,451,000 Current liabilities 68,281,000 Stockholders equity 331,883,000 Net current assets 38,432,000 ADAMAS PHARMACEUTICALS INC Total Revenues 175 Cost & expenses 16,232 14,163 Operating income (16,232) (13,988) Net income (16,028) (13,828) Primary $(072) $(065) Fully Diluted $(072) $(065) Full Diluted 22,206 21,253 Year-end 22,322 21,473 Cash & equivalents 20,918 Current assets 115,236 Net property & equip 3,138 Total assets 128,498 Current liabilities 8,261 Stockholders equity 119,745 Net current assets 106,975 ADDUS HOMECARE CORP Acquisition Development On May 4, 2017, Co announced that it has signed a definitive agreement to acquire Options Home Care, a wholly-owned subsidiary of HB Management Group and a provider of personal care services in more than 20 counties in New Mexico Terms of the transaction were not disclosed ADDUS HOMECARE CORP Dismissal of Accountant On May 9, 2017, Co dismissed BDO USA, LLP as its independent public accounting firm ADDUS HOMECARE CORP Cost & expenses 93,129 90,471 Deprec, depl & amort 1,516 1,478 Operating income 6, Interest income 7 7 Interest expense Other income (expense), net 57

4 768 MERGENT OTC INDUSTRIAL NEWS May 26, 2017 Net before taxes 6, Income taxes 2, Net income 4, Primary $037 $001 Fully Diluted $037 $001 Full Diluted 11,581 11,178 Year-end 11,628 11,136 Cash & equivalents 19,156 Current assets 139,289 Net property & equip 7,049 Total assets 238,664 Current liabilities 52,219 Long-term debt 21,877 Stockholders equity 164,568 Net current assets 87,070 ADDUS HOMECARE CORP New Accountant On Apr 21, 2017, Co dismissed BDO USA, LLP as its independent public accounting firm On Apr 25, 2017, Co engaged Ernst & Young LLP as its new independent public accounting firm ADDVANTAGE TECHNOLOGIES GROUP, INC Earnings, 6 mos to Mar 31(Consol $): Total Revenues 23,390,582 18,836,855 Cost & expenses 22,876,773 18,411,891 Operating income 513, ,964 Interest income 2,172 Other income (expense), net 109,554 Gains or losses (140,998) Net before taxes 319, ,624 Income taxes 92,000 96,000 Net income 227, ,624 Primary $002 $002 Fully Diluted $002 $002 Full Diluted 10,145,112 10,080,729 Year-end 10,192,244 10,134,235 ADTRAN, INC Net Sales 170,279, ,204,000 Cost & expenses 163,247, ,683,000 Operating income 7,032,000 5,521,000 Interest expense 141, ,000 Other income (expense), net 51, ,000 Invest income 470,000 1,728,000 Net before taxes 8,345,000 8,078,000 Income taxes 1,694,000 3,064,000 Net income 6,651,000 5,014,000 Primary $014 $010 Fully Diluted $014 $010 Full Diluted 48,939,000 49,389,000 Year-end 48,321,000 48,993,000 Cash & equivalents 72,558,000 Inventories 112,774,000 Current assets 354,400,000 Net property & equip 83,514,000 Total assets 667,178,000 Current liabilities 121,629,000 Long-term debt 26,800,000 Stockholders equity 482,213,000 Net current assets 232,771,000 ADURO BIOTECH INC Total Revenues 3,772 4,030 Cost & expenses 28,850 29,926 Operating income (25,210) (26,033) Other income (expense), net (4) (22) Net before taxes (24,564) (25,601) Income taxes (2,752) 3,226 Net income (21,812) (28,827) Primary $(032) $(045) Fully Diluted $(032) $(045) Full Diluted 68,242 63,802 Year-end 69,753 64,560 Cash & equivalents 353,961 Current assets 360,920 Net property & equip 26,443 Total assets 435,494 Current liabilities 28,821 Stockholders equity 229,017 Net current assets 332,099 ADVANCED EMISSIONS SOLUTIONS INC Total Revenues 7,389,000 22,357,000 Cost & expenses 10,618,000 25,437,000 Deprec, depl & amort 482, ,000 Operating income (3,711,000) (3,311,000) Other income (expense), net 18,478,000 9,704,000 Net before taxes 14,074,000 4,429,000 Income taxes 5,386,000 53,000 Net income 8,688,000 4,376,000 Balance for common 8,588,000 4,344,000 Primary $039 $020 Fully Diluted $039 $020 Full Diluted 22,243,000 22,176,000 Year-end 22,072,056 Cash & equivalents 28,442,000 Current assets 42,423,000 Net property & equip 504,000 Total assets 104,775,000 Current liabilities 14,942,000 Stockholders equity 85,281,000 Net current assets 27,481,000 ADVANCED ENERGY INDUSTRIES INC Net Sales 149, ,044 Cost & expenses 105,121 78,365 Operating income 43,268 23,621 Other income (expense), net (3,208) 357 Net before taxes 40,060 23,978 Income taxes 4,619 3,758 Income contin oper 35,441 20,220 Income discont oper 2,094 2,061 Net income 37,535 22,281 Primary $094 $056 Fully Diluted $093 $056 Full Diluted 40,179 40,100 Year-end 39,773 39,906 Cash & equivalents 317,949 Inventories 64,626 Current assets 482,811 Net property & equip 13,795 Total assets 616,511 Current liabilities 99,111 Stockholders equity 434,326 Net current assets 383,700 ADVERUM BIOTECHNOLOGIES INC Cost & expenses 17,050 15,773 Operating income (16,588) (15,508) Other income (expense), net Net income (16,099) (15,392) Primary $(038) $(057) Fully Diluted $(038) $(057) Full Diluted 42,144 27,095 Year-end 42,780 27,095 Cash & equivalents 71,569 Current assets 212,640 Net property & equip 4,149 Total assets 221,929 Current liabilities 11,966 Stockholders equity 201,381 Net current assets 200,674 ADVISORY BOARD COMPANY (THE) Total Revenues 194, ,735 Cost & expenses 170, ,172 Operating income 1,620 20,796 Interest expense 4,500 4,821 Other income (expense), net Equity earnings (21,577) 34 Net before taxes (2,647) 16,036 Income taxes (724) 5,663 Net income 19,654 10,339 Primary $049 $025 Fully Diluted $048 $025 Full Diluted 41,041 41,873 Year-end 40,391 40,875 Cash & equivalents 150,080 Current assets 720,946 Net property & equip 162,668 Total assets 2,034,768 Current liabilities 690,668 Long-term debt 545,420 Stockholders equity 548,416 Net current assets 30,278 AEGION CORP Total Revenues 325, ,908 Cost & expenses 311, ,047 Operating income 14,133 (4,139) Interest income Interest expense 4,047 3,615 Other income (expense), net (387) (973) Net before taxes 9,748 (8,695) Income taxes 1,995 (4,746) Net income 7,753 (3,949) Primary $017 $(011) Fully Diluted $017 $(011) Full Diluted 34,505 35,489 Year-end 33,605 35,156 Cash & equivalents 87,602 Inventories 69,113 Current assets 511,906 Net property & equip 156,690 Total assets 1,175,402 Current liabilities 203,270 Long-term debt 354,427 Stockholders equity 571,320 Net current assets 308,636 AEGLEA BIOTHERAPEUTICS INC

5 May 26, 2017 MERGENT OTC INDUSTRIAL NEWS 769 Cost & expenses 7,313 5,426 Operating income (6,331) (4,567) Interest income Other income (expense), net (11) (6) Net income (6,247) (4,547) Primary $(047) $(710) Fully Diluted $(047) $(710) Full Diluted 13, Year-end 13, Cash & equivalents 16,801 Current assets 60,305 Net property & equip 822 Total assets 61,267 Current liabilities 3,957 Stockholders equity 57,183 Net current assets 56,348 AERIE PHARMACEUTICALS INC Cost & expenses 25,429 22,110 Operating income (25,429) (22,110) Other income (expense), net Net before taxes (25,741) (22,658) Income taxes Net income (25,787) (22,704) Balance for common (25,787) (22,704) Primary $(076) $(085) Fully Diluted $(076) $(085) Full Diluted 33,777 26,723 Year-end 33,635 26,518 Cash & equivalents 139,534 Current assets 210,215 Net property & equip 12,532 Total assets 225,408 Current liabilities 13,562 Long-term debt 123,615 Stockholders equity 84,116 Net current assets 196,653 AEVI GENOMIC MEDICINE INC Cost & expenses 10,935 11,142 Operating income (10,935) (11,142) Other income (expense), net 18 (2) Net income (10,917) (11,144) Primary $(029) $(034) Fully Diluted $(029) $(034) Full Diluted 37,108 32,954 Year-end 37,110 33,211 Cash & equivalents 29,203 Current assets 30,185 Net property & equip 336 Total assets 30,532 Current liabilities 5,450 Stockholders equity 25,082 Net current assets 24,735 AGILE THERAPEUTICS INC Cost & expenses 7,126,000 6,980,000 Operating income (7,126,000) (6,980,000) Interest income 47,000 17,000 Interest expense 546, ,000 Gains or losses 109, ,000 Net income (7,516,000) (7,318,000) Primary $(026) $(027) Fully Diluted $(026) $(027) Full Diluted 28,769,361 26,826,223 Year-end 28,776,398 28,738,050 Cash & equivalents 41,744,000 Current assets 44,269,000 Net property & equip 12,330,000 Total assets 56,617,000 Current liabilities 11,592,000 Long-term debt 9,416,000 Stockholders equity 35,609,000 Net current assets 32,677,000 AGIOS PHARMACEUTICALS INC Cost & expenses 77,555 54,875 Operating income (67,047) (23,594) Interest income Net income (66,166) (23,198) Primary $(156) $(061) Fully Diluted $(156) $(061) Full Diluted 42,281 37,864 Year-end 42,383 37,899 Cash & equivalents 200,278 Current assets 506,866 Net property & equip 24,139 Total assets 557,316 Current liabilities 82,429 Stockholders equity 307,380 Net current assets 424,437 AGIOS PHARMACEUTICALS INC New Accountant On May 5, 2017, Co dismissed Ernst & Young LLP and engaged PricewaterhouseCoopers LLP as its new independent public accounting firm AGNC INVESTMENT CORP Cost & expenses 115, ,000 Net income 76,000 (772,000) Balance for common 69,000 (779,000) Primary $021 $(233) Fully Diluted $021 $(233) Full Diluted 331, ,400 Year-end 331, ,000 Cash & equivalents 1,073,000 Current assets 1,980,000 Total assets 56,838,000 Current liabilities 49,043,000 Long-term debt 434,000 Stockholders equity 7,292,000 Net current assets (47,063,000) AGROFRESH SOLUTIONS INC Net Sales 32,730,000 28,411,000 Cost & expenses 25,782,000 44,815,000 Operating income (3,497,000)(26,303,000) Interest expense 10,293,000 15,008,000 Other income (expense), net 40,000 55,000 Foreign currency 3,103, ,000 Net before taxes (10,647,000)(40,426,000) Income taxes 1,382,000 (15,289,000) Net income (12,029,000)(25,137,000) Primary $(024) $(051) Fully Diluted $(024) $(051) Full Diluted 49,661,469 49,718,153 Year-end 50,280,826 49,900,795 Cash & equivalents 84,858,000 Inventories 16,156,000 Current assets 169,823,000 Net property & equip 7,748,000 Total assets 954,996,000 Current liabilities 84,608,000 Long-term debt 403,431,000 Stockholders equity 321,502,000 Net current assets 85,215,000 AIMMUNE THERAPEUTICS INC Cost & expenses 26,341 15,699 Operating income (26,341) (15,699) Interest income Net income (25,870) (15,523) Primary $(052) $(037) Fully Diluted $(052) $(037) Full Diluted 50,069 41,694 Year-end 50,204 42,241 Cash & equivalents 78,714 Current assets 248,872 Net property & equip 11,147 Total assets 276,289 Current liabilities 10,223 Stockholders equity 264,718 Net current assets 238,649 AIR TRANSPORT SERVICES GROUP, INC Total Revenues 237, ,385 Cost & expenses 183, ,500 Deprec, depl & amort 36,442 32,534 Operating income 17,753 15,351 Interest income Interest expense 3,548 2,699 Other income (expense), net 1,869 (528) Net before taxes 16,106 12,148 Income taxes 6,310 3,977 Income contin oper 9,796 8,171 Net income 9,988 8,218 Primary $017 $013 Fully Diluted $013 $013 Full Diluted 64,949 65,057 Year-end 59,564 64,069 Cash & equivalents 27,631 Inventories 18,454 Current assets 154,547 Net property & equip 1,057,877 Total assets 1,340,811 Current liabilities 164,618 Long-term debt 481,886 Stockholders equity 341,083 Net current assets (10,071) AKAMAI TECHNOLOGIES INC Total Revenues 609, ,725 Cost & expenses 486, ,890 Operating income 115, ,119 Interest income 4,624 3,320 Interest expense 4,597 4,653

6 770 MERGENT OTC INDUSTRIAL NEWS May 26, 2017 Other income (expense), net (684) (189) Net before taxes 114, ,597 Income taxes 33,641 37,739 Net income 80,930 74,858 Primary $047 $042 Fully Diluted $046 $042 Full Diluted 175, ,539 Year-end 174, ,050 Cash & equivalents 522,319 Current assets 1,398,461 Net property & equip 824,724 Total assets 4,449,995 Current liabilities 381,876 Long-term debt 645,719 Stockholders equity 3,258,546 Net current assets 1,016,585 AKEBIA THERAPEUTICS INC Cost & expenses 65,837,000 26,046,000 Operating income (44,972,000)(26,046,000) Other income (expense), net (6,000) 14,000 Net income (44,543,000)(25,798,000) Primary $(115) $(070) Fully Diluted $(115) $(070) Full Diluted 38,759,221 36,873,594 Year-end 38,829,562 37,946,010 Cash & equivalents 87,250,000 Current assets 255,053,000 Net property & equip 2,904,000 Total assets 259,256,000 Current liabilities 133,463,000 Stockholders equity 30,617,000 Net current assets 121,590,000 AKORN INC Total Revenues 253, ,347 Cost & expenses 163, ,250 Operating income 74,833 87,579 Other income (expense), net 59 (9,489) Net before taxes 65,326 66,572 Income taxes 24,299 24,686 Net income 41,027 41,886 Primary $033 $035 Fully Diluted $033 $034 Full Diluted 124, ,621 Year-end 124, ,427 Cash & equivalents 307,425 Inventories 172,325 Current assets 735,950 Net property & equip 252,656 Total assets 2,025,737 Current liabilities 174,844 Long-term debt 811,283 Stockholders equity 870,412 Net current assets 561,106 ALARMCOM HOLDINGS INC Total Revenues 74,194 59,043 Cost & expenses 66,845 53,191 Operating income 4,485 4,261 Interest expense Other income (expense), net Net before taxes 4,506 4,331 Income taxes 543 1,593 Net income 3,963 2,738 Balance for common 3,961 2,733 Primary $009 $006 Fully Diluted $008 $006 Full Diluted 48,759 47,304 Year-end 46,283 45,581 Cash & equivalents 63,150 Inventories 7,289 Current assets 119,259 Net property & equip 20,788 Total assets 335,640 Current liabilities 41,003 Long-term debt 73,700 Stockholders equity 198,407 Net current assets 78,256 ALASKA COMMUNICATIONS SYSTEMS GROUP INC Total Revenues 56,731 56,328 Cost & expenses 43,254 43,492 Deprec, depl & amort 8,903 8,520 Operating income 4,574 4,316 Other income (expense), net (2,276) (336) Net before taxes (1,540) 116 Income taxes (832) 63 Net income (708) 53 Primary $(001) $ Fully Diluted $(001) $ Full Diluted 52,011 51,637 Year-end 52,341 51,231 Cash & equivalents 11,978 Inventories 5,281 Current assets 148,620 Net property & equip 363,570 Total assets 529,332 Current liabilities 45,320 Long-term debt 265,060 Stockholders equity 157,370 Net current assets 103,300 ALBANY MOLECULAR RESEARCH INC Total Revenues 163,822, ,579,000 Cost & expenses 161,741, ,731,000 Operating income 2,081,000 (4,152,000) Other income (expense), net (793,000) (997,000) Net before taxes (11,542,000)(12,285,000) Income taxes (850,000) (2,218,000) Net income (10,692,000)(10,067,000) Primary $(025) $(029) Fully Diluted $(025) $(029) Full Diluted 42,385,000 34,718,000 Year-end 42,932,000 35,708,000 Cash & equivalents 35,193,000 Inventories 174,043,000 Current assets 385,150,000 Net property & equip 360,282,000 Total assets 1,163,529,000 Current liabilities 167,012,000 Long-term debt 607,246,000 Stockholders equity 296,799,000 Net current assets 218,138,000 ALCENTRA CAPITAL CORP Cost & expenses 4,224,859 4,076,869 Net income 4,592,616 5,604,892 Primary $034 $041 Fully Diluted $008 $032 Full Diluted 13,438,800 13,515,498 Year-end 13,437,059 13,506,257 Cash & equivalents 4,719,733 Current assets 7,191,278 Total assets 293,892,116 Current liabilities 59,872,682 Long-term debt 53,600,991 Stockholders equity 180,418,443 Net current assets (52,681,404) ALDER BIOPHARMACEUTICALS INC Cost & expenses 100,670 33,692 Operating income (100,670) (33,692) Interest income Equity earnings 149 Foreign currency 6 (86) Net income (100,328) (33,363) Primary $(199) $(076) Fully Diluted $(199) $(076) Full Diluted 50,396 43,754 Year-end 50,410 43,758 Cash & equivalents 79,713 Inventories 936 Current assets 310,327 Net property & equip 6,776 Total assets 317,849 Current liabilities 29,635 Stockholders equity 287,759 Net current assets 280,692 ALEXION PHARMACEUTICALS INC Total Revenues 870,000, ,000,000 Cost & expenses 578,000, ,000,000 Operating income 212,000, ,000,000 Interest expense 24,000,000 24,000,000 Other income (expense), net 2,000,000 Gains or losses 4,000,000 1,000,000 Net before taxes 194,000, ,000,000 Income taxes 24,000,000 51,000,000 Net income 170,000,000 92,000,000 Primary $076 $041 Fully Diluted $075 $041 Full Diluted 226,000, ,000,000 Year-end 224,000, ,202,000 Cash & equivalents 713,000,000 Inventories 396,000,000 Current assets 2,733,000,000 Net property & equip 1,138,000,000 Total assets 13,435,000,000 Current liabilities 837,000,000 Long-term debt 3,116,000,000 Stockholders equity 8,856,000,000 Net current assets 1,896,000,000 ALICO, INC Earnings, 6 mos to Mar 31(Consol $):

7 May 26, 2017 MERGENT OTC INDUSTRIAL NEWS 771 Total Revenues 73,645,000 92,493,000 Cost & expenses 63,563,000 78,386,000 Operating income 10,082,000 14,107,000 Other income (expense), net (71,000) (300,000) Gains or losses 1,832, ,000 Net before taxes 7,189,000 9,731,000 Income taxes 3,048,000 4,027,000 Net income 4,141,000 5,704,000 Balance for common 4,098,000 5,722,000 Primary $049 $069 Fully Diluted $049 $069 Full Diluted 8,326,000 8,309,000 Year-end 8,306,319 8,302,063 ALIGN TECHNOLOGY INC Total Revenues 310, ,720 Cost & expenses 248, ,386 Operating income 61,673 53,334 Other income (expense), net 1,645 (427) Equity earnings 1,121 Net before taxes 63,318 52,907 Income taxes (7,223) 12,361 Net income 69,420 40,546 Primary $087 $051 Fully Diluted $085 $050 Full Diluted 81,534 81,320 Year-end 80,324 80,175 Cash & equivalents 261,027 Inventories 35,174 Current assets 918,167 Net property & equip 231,692 Total assets 1,459,293 Current liabilities 365,554 Stockholders equity 1,044,875 Net current assets 552,613 ALIMERA SCIENCES, INC Total Revenues 6,618 5,801 Cost & expenses 11,463 13,902 Operating income (5,511) (8,790) Other income (expense), net 167 (1,045) Foreign currency (28) 34 Net before taxes (6,709) (11,136) Income taxes 26 9 Net income (6,735) (11,145) Primary $(010) $(025) Fully Diluted $(010) $(025) Full Diluted 64,863 45,006 Year-end 64,863 45,006 Cash & equivalents 26,737 Inventories 802 Current assets 40,450 Net property & equip 1,572 Total assets 62,590 Current liabilities 6,777 Long-term debt 33,593 Stockholders equity 20,066 Net current assets 33,673 ALJ REGIONAL HOLDINGS INC Acquisition Development On May 16, 2017, Co s whollyowned subsidiary, Faneuil, Inc ("Faneuil"), announced it has entered into an asset purchase agreement (the "Agreement") to acquire the BPO and contact center operations of Vertex Business Services LLC ("Vertex"), a direct customer care provider of contact centers and back-office processes, including billing, collections and business analytics, and installing and supporting cloudbased customer care and billing technologies exclusively for the utilities industry Pursuant to the terms and subject to the conditions of the Purchase Agreement, Faneuil will acquire certain assets and assume certain liabilities from Vertex in respect of Vertex s BPO and contact center operations As consideration for the acquisition, Faneuil will pay an aggregate purchase price of$13,000,000 consisting of (i) $8,132,392 in cash consideration, subject to customary net working capital adjustments at closing, and (ii) 1,466,667 shares of Co s common stock in stock consideration, valued using the thirty-day weighted-average closing price of $332 per sharefaneuil will place 391,566 shares of Co s common stock issued as stock consideration in an escrow account at closing to secure any Vertex obligation to indemnify Faneuil for breaches by Vertex of its representations and warranties and covenants under the Purchase Agreement, or potentially in the event of any working capital adjustment in favor of Faneuil ALJ REGIONAL HOLDINGS INC Earnings, 6 mos to Mar 31(Consol $): Total Revenues 156,913, ,076,000 Cost & expenses 150,497, ,611,000 Operating income 6,416,000 5,465,000 Interest expense 4,718,000 4,526,000 Net before taxes 1,698, ,000 Income taxes 755, ,000 Net income 943, ,000 Primary $003 $002 Fully Diluted $003 $002 Full Diluted 35,671,000 36,181,686 Year-end 34,574,641 35,003,212 ALLEGIANT TRAVEL COMPANY Total Revenues 375, ,615 Cost & expenses 272, ,804 Deprec, depl & amort 30,549 24,685 Operating income 72, ,126 Other income (expense), net Net before taxes 66, ,862 Income taxes 24,479 42,882 Net income 41,632 71,980 Balance for common 40,950 71,610 Primary $250 $429 Fully Diluted $250 $429 Full Diluted 16,404 16,699 Year-end 16,637 16,528 Cash & equivalents 64,732 Inventories 16,345 Current assets 426,147 Net property & equip 1,121,230 Total assets 1,749,744 Current liabilities 444,340 Long-term debt 715,383 Stockholders equity 503,102 Net current assets (18,193) ALLIANCE HEALTHCARE SERVICES INC Total Revenues 129, ,725 Cost & expenses 108, ,029 Operating income 4,122 2,205 Equity earnings (336) (252) Net before taxes 4,122 2,205 Income taxes (3) (945) Net income 4,461 3,402 Primary $(006) $(011) Fully Diluted $(006) $(011) Full Diluted 10,973 10,779 Year-end 10,831 10,717 Cash & equivalents 21,472 Current assets 108,511 Net property & equip 194,334 Total assets 645,642 Current liabilities 99,874 Long-term debt 520,333 Stockholders equity (139,766) Net current assets 8,637 ALLIANCE HOLDINGS GROUP LP Total Revenues 461, ,725 Cost & expenses 288, ,414 Deprec, depl & amort 65,127 80,883 Operating income 107,043 54,428 Interest income 25 4 Interest expense 7,516 7,615 Other income (expense), net 4, Net before taxes 104,550 46,881 Income taxes (12) (8) Net income 104,562 46,889 Primary $092 $052 Fully Diluted $092 $052 Full Diluted 59,863 59,863 Year-end 59,863 59,863 Cash & equivalents 92,028 Inventories 77,871 Current assets 309,811 Net property & equip 1,551,685 Total assets 2,208,813 Current liabilities 323,527 Long-term debt 447,058 Net current assets (13,716) ALLIANCE RESOURCE PARTNERS LP Total Revenues 461, ,829 Cost & expenses 288, ,099 Operating income 107,532 54,847 Interest income 24 3 Interest expense 7,516 7,615 Other income (expense), net 4, Net before taxes 105,038 47,299 Income taxes (12) (9) Net income 105,050 47,308 Primary $110 $036 Fully Diluted $110 $036 Full Diluted 74,503 74,291 Year-end 74,597 74,375 Cash & equivalents 87,360 Inventories 77,871 Current assets 305,372 Net property & equip 1,551,685 Total assets 2,204,316 Current liabilities 323,034 Long-term debt 447,058 Net current assets (17,662) ALLIED MOTION TECHNOLOGIES INC Total Revenues 61,354 63,675 Cost & expenses 56,196 58,136 Operating income 4,365 4,760 Interest expense 523 1,532 Other income (expense), net 10 (15) Net before taxes 3,852 3,213 Income taxes 1, Net income 2,657 2,355 Primary $029 $025 Fully Diluted $029 $025 Full Diluted 9,229 9,273 Year-end 9,471 9,402

8 772 MERGENT OTC INDUSTRIAL NEWS May 26, 2017 Cash & equivalents 14,048 Inventories 30,862 Current assets 78,989 Net property & equip 37,370 Total assets 182,426 Current liabilities 26,068 Long-term debt 67,592 Stockholders equity 76,417 Net current assets 52,921 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC Total Revenues 413,475, ,558,000 Cost & expenses 394,900, ,500,000 Operating income 11,263,000 11,896,000 Interest expense 20,180,000 6,969,000 Other income (expense), net 239, ,000 Gains or losses 285,000 (2,603,000) Net before taxes (8,393,000) 2,690,000 Income taxes 172, ,000 Net income (8,565,000) 2,127,000 Balance for common (19,980,000) 2,049,000 Primary $(011) $001 Fully Diluted $(011) $001 Full Diluted 180,767, ,741,000 Year-end 181,464, ,974,000 Cash & equivalents 104,391,000 Current assets 627,161,000 Net property & equip 153,197,000 Total assets 3,799,018,000 Current liabilities 698,388,000 Long-term debt 1,298,045,000 Stockholders equity 1,147,788,000 Net current assets (71,227,000) ALMOST FAMILY INC Earnings, 3 mos to (Consol $): 03/31/17 04/01/16 Cost & expenses 194,248, ,962,000 Operating income 7,064,000 7,736,000 Other income (expense), net (760,000) 190,000 Net before taxes 4,407,000 6,594,000 Income taxes 774,000 2,677,000 Net income 3,633,000 3,917,000 Primary $029 $039 Fully Diluted $028 $038 Full Diluted 12,937,000 10,260,000 Year-end 13,938,000 10,490,000 Cash & equivalents 13,891,000 Current assets 153,150,000 Net property & equip 13,598,000 Total assets 716,277,000 Current liabilities 72,671,000 Long-term debt 129,726,000 Stockholders equity 450,070,000 Net current assets 80,479,000 ALNYLAM PHARMACEUTICALS INC Total Revenues 18,960 7,345 Cost & expenses 125, ,373 Operating income (106,511) (110,028) Interest income 2,128 1,813 Other income (expense), net (2,907) 5,241 Net income (107,290) (102,974) Primary $(125) $(121) Fully Diluted $(125) $(121) Full Diluted 86,027 85,277 Year-end 86,068 85,463 Cash & equivalents 171,079 Current assets 597,188 Net property & equip 129,962 Total assets 1,133,926 Current liabilities 95,786 Long-term debt 150,000 Stockholders equity 830,901 Net current assets 501,402 ALPHATEC HOLDINGS INC Total Revenues 27,978,000 34,206,000 Cost & expenses 31,205,000 37,393,000 Operating income (3,399,000) (3,442,000) Interest expense 1,981, ,000 Other income (expense), net 5, ,000 Net before taxes (5,375,000) (4,225,000) Income taxes 49,000 23,000 Income contin oper (5,424,000) (4,248,000) Net income (5,515,000) (6,617,000) Primary $(061) $(078) Fully Diluted $(061) $(078) Full Diluted 9,005,000 8,466,000 Year-end 10,858,000 Cash & equivalents 25,485,000 Inventories 30,088,000 Current assets 72,406,000 Net property & equip 15,408,000 Total assets 93,571,000 Current liabilities 33,327,000 Long-term debt 40,017,000 Stockholders equity (29,133,000) Net current assets 39,079,000 ALTIMMUNE INC Cost & expenses 3,954,387 2,222,429 Operating income (3,183,323) (1,254,436) Other income (expense), net (90,566) 44,017 Net before taxes (3,198,912) (1,211,469) Income taxes (1,001,315) 15,437 Net income (2,197,597) (1,226,906) Primary $(003) $(002) Fully Diluted $(003) $(002) Full Diluted 68,737,093 64,404,396 Year-end 68,815,195 64,444,725 Cash & equivalents 15,782,402 Current assets 18,292,087 Net property & equip 87,937 Total assets 20,728,477 Current liabilities 2,234,580 Stockholders equity 18,051,308 Net current assets 16,057,507 ALTIMMUNE INC Merger Completed On May 4, 2017, Co s wholly-owned subsidiary, Mustang Merger Sub Corp I Inc ("Merger Sub Corp"), merged with and into Altimmune, Inc ("Altimmune"), with Altimmune continuing as the surviving corporation in such merger ("Merger 1"), and immediately thereafter, Altimmune merged with and into Co s wholly-owned subsidiary, Mustang Merger Sub II LLC ("Merger Sub LLC"), with Merger Sub LLC continuing as the surviving entity in such merger ("Merger 2" and together with Merger 1, each a "Merger" and collectively the "Mergers") As the result of the mergers, Co issued shares of its common stock to Altimmune s stockholders, at an exchange ratio of of a share of common stock (post the Reverse Stock Split), in exchange for each share of Altimmune common stock outstanding as of the Effective Time Co also assumed all of the Altimmune stock options and warrants, with such stock options and warrants henceforth representing the right to purchase a number of shares of Co s common stock equal to multiplied by the number of shares of Altimmune s common stock previously represented by such stock options and warrants, as applicable Immediately following the Effective Time, the former Altimmune stockholders, warrantholders and optionholders owned 582% of Co, with Co s stockholders, warrantholders and optionholders immediately prior to the Mergers, whose warrants, options and shares of Co s common stock remain outstanding after the Mergers, owning 418% of Co As the result Co changed its name to Altimmune, Inc ALTIMMUNE INC New Name On May 5, 2017, Co changed its name from PharmAthene Inc to Altimmune Inc ALTIMMUNE INC Stock Trading Status Co s Class A common stock is trading on NASDAQ National Market System (NMS), Symbol ALT ALTISOURCE PORTFOLIO SOLUTIONS SA Total Revenues 240, ,132 Cost & expenses 214, ,663 Operating income 14,829 27,653 Other income (expense), net 617 (38) Net before taxes 9,746 21,085 Income taxes 2,586 2,193 Net income 7,160 18,892 Primary $035 $098 Fully Diluted $034 $092 Full Diluted 19,304 20,040 Year-end 18,413 18,603 Cash & equivalents 180,300 Current assets 310,695 Net property & equip 96,023 Total assets 653,483 Current liabilities 104,922 Long-term debt 466,510 Stockholders equity 70,914 Net current assets 205,773 ALTRA INDUSTRIAL MOTION CORP Net Sales 215, ,453 Cost & expenses 197, ,476 Operating income 17,662 14,977 Interest expense 1,705 2,896 Other income (expense), net (1,267) 278 Net before taxes 14,690 12,359 Income taxes 4,364 3,549 Net income 10,326 8,810 Primary $036 $034 Fully Diluted $036 $034 Full Diluted 28,897 25,759 Year-end 28,985 25,694 Cash & equivalents 52,937 Inventories 139,444 Current assets 349,068 Net property & equip 178,504 Total assets 877,528 Current liabilities 128,166 Long-term debt 317,649 Stockholders equity 347,447 Net current assets 220,902 AMAG PHARMACEUTICALS, INC

9 May 26, 2017 MERGENT OTC INDUSTRIAL NEWS 773 Total Revenues 139,472, ,300,000 Cost & expenses 179,496, ,852,000 Operating income (40,024,000) 7,448,000 Interest expense 18,300,000 18,443,000 Other income (expense), net 220,000 Gains or losses 27,000 Net before taxes (57,266,000)(10,067,000) Income taxes (20,706,000) (2,540,000) Net income (36,560,000) (7,527,000) Primary $(106) $(022) Fully Diluted $(106) $(022) Full Diluted 34,378,000 34,739,000 Year-end 34,445,394 34,568,568 Cash & equivalents 252,854,000 Inventories 36,927,000 Current assets 688,871,000 Net property & equip 22,708,000 Total assets 2,421,910,000 Current liabilities 307,939,000 Long-term debt 964,899,000 Stockholders equity 924,088,000 Net current assets 380,932,000 AMAZONCOM INC Net Sales 35,714,000 29,128,000 Cost & expenses 34,709,000 28,057,000 Operating income 1,005,000 1,071,000 Interest income 39,000 21,000 Interest expense 139, ,000 Other income (expense), net 48,000 81,000 Equity earnings 68,000 Net before taxes 953,000 1,056,000 Income taxes 229, ,000 Net income 724, ,000 Primary $152 $109 Fully Diluted $148 $107 Full Diluted 490, ,000 Year-end 478, ,000 Cash & equivalents 15,440,000 Inventories 10,600,000 Current assets 39,460,000 Net property & equip 32,632,000 Total assets 80,969,000 Current liabilities 37,399,000 Long-term debt 7,691,000 Stockholders equity 21,674,000 Net current assets 2,061,000 AMC NETWORKS INC Total Revenues 720, ,579 Cost & expenses 465, ,140 Operating income 231, ,807 Interest income 3, Interest expense 30,500 31,751 Other income (expense), net 11,049 (49,171) Net before taxes 215, ,607 Income taxes 73,082 58,543 Net income 142, ,064 Primary $200 $156 Fully Diluted $198 $155 Full Diluted 68,764 73,274 Year-end 67,235 72,675 Cash & equivalents 403,648 Current assets 1,653,987 Net property & equip 169,223 Total assets 4,470,054 Current liabilities 965,611 Long-term debt 2,559,705 Stockholders equity 31,452 Net current assets 688,376 AMEDISYS, INC Cost & expenses 340,876, ,281,000 Operating income 25,165,000 11,063,000 Interest income 19,000 22,000 Interest expense 1,068,000 1,112,000 Other income (expense), net 1,006, ,000 Net before taxes 25,122,000 10,703,000 Income taxes 9,923,000 4,388,000 Net income 15,199,000 6,315,000 Primary $045 $019 Fully Diluted $044 $019 Full Diluted 34,073,000 33,508,000 Year-end 33,693,027 33,340,512 Cash & equivalents 48,334,000 Current assets 243,102,000 Net property & equip 36,676,000 Total assets 756,628,000 Current liabilities 183,904,000 Long-term debt 85,500,000 Stockholders equity 481,980,000 Net current assets 59,198,000 AMERICAN PUBLIC EDUCATION INC Total Revenues 75,688 83,966 Cost & expenses 62,637 63,107 Deprec, depl & amort 4,744 4,889 Operating income 8,307 15,970 Equity earnings (40) (600) Net before taxes 8,318 16,007 Income taxes 3,849 6,267 Net income 4,509 10,340 Primary $028 $064 Fully Diluted $028 $064 Full Diluted 16,321 16,171 Year-end 16,233 16,055 Cash & equivalents 147,804 Current assets 165,634 Net property & equip 95,728 Total assets 320,317 Current liabilities 39,833 Stockholders equity 269,121 Net current assets 125,801 AMERICAN RAILCAR INDUSTRIES INC Total Revenues 114, ,180 Cost & expenses 92, ,483 Operating income 21,915 40,697 Other income (expense), net 604 1,486 Net before taxes 17,361 36,755 Income taxes 6,793 13,963 Net income 10,568 22,792 Primary $055 $116 Fully Diluted $055 $116 Full Diluted 19,084 19,665 Year-end 19,084 19,561 Cash & equivalents 151,246 Inventories 78,811 Current assets 294,712 Net property & equip 173,069 Total assets 1,459,637 Current liabilities 88,647 Long-term debt 539,076 Stockholders equity 552,505 Net current assets 206,065 AMERISAFE INC Total Revenues 97, ,335 Cost & expenses 78,809 67,940 Operating income 18,733 34,395 Net before taxes 18,733 34,395 Income taxes 5,209 10,138 Net income 13,524 24,257 Balance for common 13,524 24,257 Primary $071 $127 Fully Diluted $070 $127 Full Diluted 19,230 19,164 Year-end 19,230 19,182 Cash & equivalents 39,353 Current assets 358,237 Net property & equip 6,441 Total assets 1,536,536 Current liabilities 122,824 Stockholders equity 467,101 Net current assets 235,413 AMGEN INC Total Revenues 5,464,000 5,527,000 Cost & expenses 2,873,000 3,125,000 Operating income 2,591,000 2,402,000 Interest expense 326, ,000 Net before taxes 2,460,000 2,258,000 Income taxes 389, ,000 Net income 2,071,000 1,900,000 Primary $281 $252 Fully Diluted $279 $250 Full Diluted 741, ,000 Year-end 736, ,300 Cash & equivalents 3,358,000 Inventories 2,871,000 Current assets 46,456,000 Net property & equip 4,960,000 Total assets 77,862,000 Current liabilities 10,523,000 Long-term debt 30,293,000 Stockholders equity 30,637,000 Net current assets 35,933,000 AMICUS THERAPEUTICS INC Net Sales 4,169,000 Cost & expenses 55,361,000 42,328,000 Operating income (52,015,000)(43,001,000) Interest income 759, ,000 Interest expense 4,290, ,000 Other income (expense), net 610,000 (52,000) Net before taxes (54,936,000) Income taxes 56,000 Net income (54,992,000)(43,691,000) Primary $(039) $(035) Fully Diluted $(039) $(035)